Welcome to our dedicated page for THIOGENESIS THERAPEUTICS news (Ticker: TTIPF), a resource for investors and traders seeking the latest updates and insights on THIOGENESIS THERAPEUTICS stock.
Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company developing sulfur-containing and thiol-based prodrugs for serious pediatric and inherited diseases, particularly rare mitochondrial and metabolic disorders. The Thiogenesis news stream highlights how its lead candidate, TTI-0102, progresses through clinical development and regulatory interactions.
News releases from the company focus heavily on clinical milestones for TTI-0102. These include updates on its randomized, double-blind, placebo-controlled Phase 2 trial in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in Europe, interim analyses describing biomarker activity and biological proof-of-concept, and activation of additional European trial sites. Thiogenesis also reports on plans and regulatory clearances for a Phase 2a trial in Leigh syndrome spectrum in the United States, as well as preparations for a Phase 3 pivotal trial in nephropathic cystinosis and a Phase 2 or Phase 2a trial in pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Investors and observers can use the TTIPF news page to follow announcements about scientific presentations at mitochondrial disease conferences, late-breaking abstract acceptances, and participation in webinars and panel discussions organized by patient advocacy and research organizations. Corporate updates such as private placements, stock option grants, investor relations agreements, and patent developments related to asymmetric disulfide prodrugs of cysteamine are also reflected in the news flow.
By reviewing Thiogenesis Therapeutics news, readers gain insight into the timing and design of its clinical trials, the company’s focus on mitochondrial oxidative stress and thiol biology, and the regulatory guidance it receives in key jurisdictions. The news page can be revisited regularly to see how the TTIPF development pipeline and corporate strategy evolve over time based on company disclosures.
Thiogenesis Therapeutics (TTIPF) has engaged Brisco Capital Partners to provide investor relations services effective September 1, 2026. Brisco will help expand communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
Brisco will receive a monthly fee of $6,000 plus taxes and 100,000 stock options exercisable at $0.50 for 36 months, vesting quarterly over one year; the agreement and option grant are subject to TSX Venture Exchange acceptance. Thiogenesis also plans to amend its omnibus equity incentive plan, raising the share reserve from 9,099,095 to 13,995,931 common shares to restore the 20% security-based compensation limit. The amendment requires TSXV acceptance and disinterested shareholder approval at the annual and special meeting on September 8, 2026.
Thiogenesis Therapeutics (TSXV: TTI, OTCQX: TTIPF) reported that the U.S. FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate TTI-0102 for the treatment of Leigh syndrome, a serious mitochondrial disorder primarily affecting children.
According to Thiogenesis, RPD designation makes the company eligible, upon potential future NDA approval for TTI-0102, to receive a Priority Review Voucher (PRV). A PRV can be used to obtain priority review for another marketing application or sold to another sponsor, and has historically been a valuable strategic asset for biotechnology companies. The company highlighted this as an important regulatory milestone that broadens its regulatory portfolio.
Thiogenesis also noted that, since obtaining prior FDA IND clearance, it has refined the planned Phase 2 trial of TTI-0102 for the Leigh syndrome spectrum by integrating pharmacokinetic insights from its MELAS clinical program, and is completing final start-up activities before initiating the Phase 2 study.
Thiogenesis Therapeutics (OTCQX: TTIPF, TSXV: TTI) appointed Dr. Gilad Aharon, Co-Founder and Portfolio Manager at Rosalind Advisors, to its Board of Directors following Rosalind’s investment in a recent non-brokered private placement.
The TSX Venture Exchange granted final acceptance of this private placement, supporting ongoing development of cysteamine-based therapy TTI-0102 for cystinosis and primary mitochondrial diseases.
Thiogenesis Therapeutics (OTCQX: TTIPF) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 22, 2026 from 1:30–2:00 p.m. ET.
Management, including CFO Brook Riggins and CEO Patrice Rioux, will overview the company, its clinical-stage sulfur-based prodrug programs, the late-stage nephropathic cystinosis program, and expansion into mitochondrial indications such as Leigh syndrome.
Thiogenesis Therapeutics (OTCQX: TTIPF) announced an investigator-initiated study led by Dr. Larry Greenbaum to evaluate TTI-0102 in nephropathic cystinosis, focusing on once-daily dosing, tolerability, and WBC cystine control to inform Phase 3 dose optimization.
The company plans manufacturing scale-up for a newly patented salt formulation, parallel stability testing, and a planned Phase 3 non-inferiority study via the FDA 505(b)(2) pathway.
Thiogenesis (OTCQX: TTIPF) presented interim Phase 2 (EU) data for TTI-0102 in MELAS at Mitocon 2026 on January 23, 2026. The exploratory randomized, single-blind study (n=9) showed that weight-based once-daily dosing (~60 ±5 mg/kg) delivered sustained 24-hour cysteamine exposure with lower peak plasma concentrations versus fixed dosing and approved cysteamine formulations. Clinically, TTI-0102 produced a mean reduction in MFIS fatigue scores up to 10% versus placebo (p < 0.001). Pharmacodynamics included increased plasma pyruvate without lactate rise and decreased tryptophan. Fixed dosing caused gastrointestinal adverse events and discontinuations in lower-weight patients; weight-adjusted dosing mitigated these effects and informs the company’s Leigh program design.
Thiogenesis Therapeutics (OTCQX: TTIPF) announced that an abstract with preliminary Phase 2 MELAS results for oral TTI-0102 was accepted as Late-Breaking News for presentation at Mitocon Conference 2026 in Pisa, January 23–26, 2026.
The poster, titled "Pharmacokinetics and Pharmacodynamics of TTI-0102 in MELAS," will be presented during the Poster Session on January 23 and summarizes preliminary pharmacokinetic and pharmacodynamic findings from Thiogenesis' randomized, double-blind, placebo-controlled Phase 2 MELAS study. The abstract was selected by Mitocon's Scientific Committee. The company notes interim results demonstrated biological proof-of-concept and biomarker activity supporting TTI-0102's mechanism and supports continued development, including a planned Phase 2a Leigh syndrome trial in the U.S.
Thiogenesis (OTCQX: TTIPF) announced that CEO Patrice Rioux, MD, Ph.D. will present clinical updates at the United Mitochondrial Disease Foundation Bench-to-Bedside webinar on January 5, 2026. The presentation will cover the lead candidate TTI-0102, including results from a recently completed EU Phase 2 MELAS trial and plans for a Phase 2a Leigh syndrome spectrum (LSS) trial expected to begin in the first quarter of 2026 in the United States.
The company said the U.S. Phase 2a LSS trial is planned in collaboration with a leading pediatric hospital and that TTI-0102 is being developed to address mitochondrial oxidative stress, a key pathological feature across multiple inherited mitochondrial disorders for which no approved therapies currently exist.
Thiogenesis Therapeutics (OTCQX: TTIPF) plans a Phase 3 pivotal clinical trial of lead candidate TTI-0102 for nephropathic cystinosis. The company said TTI-0102 is designed to improve tolerability and simplify dosing versus existing therapies. Thiogenesis intends to submit an Investigational New Drug (IND) application in early 2026 to support initiation of the pivotal study. TTI-0102 is part of a pipeline of next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases.
Thiogenesis (OTCQX: TTIPF) reported positive blinded interim Phase 2 results for TTI-0102 in MELAS on November 4, 2025. The analysis covers nine patients (six active, three placebo) and shows biological proof-of-concept, dose discovery and biomarker improvements with clear differentiation among active patients.
Four patients under 50 kg discontinued for dose-dependent side effects, prompting planned dual dosing regimens for different weight cohorts. Final 6-month Radboud data are expected by January 2026 and an IMPD filing to enable a pivotal Phase 3 in Europe is planned for 2026. FDA accepted an IND for Leigh syndrome and a planned IND for nephropathic cystinosis targets a Phase 3 non-inferiority trial.